IL-33 receptor inhibition in subjects with uncontrolled asthma: A randomized, placebo-controlled trial

• Published in: The journal of allergy and clinical immunology. Global Vol. 1; no. 4; pp. 198 - 208
• Main Authors: Crim, Courtney, Stone, Sally, Millar, Valerie, Lettis, Sally, Bel, Elisabeth H., Menzies-Gow, Andrew, Chanez, Pascal, Wenzel, Sally, Lugogo, Njira, Bleecker, Eugene R.
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.11.2022
• Subjects: Asthma; GSK37772847; IL-1 receptor-like 1 protein; IL-33; mAb; placebo-controlled trial; randomized trial; Feno; LoAC; IL-1 receptor-like 1 protein; AE; randomized trial; FP; IL-33; Asthma; mAb; ACQ; PEF; placebo-controlled trial; SAE; LABA; ICS; GSK37772847; sIL-33R; IL-33R; T2; SAL

Most biologics for severe asthma target only type 2 immunity. Inhibition of IL-33 signaling has the potential to target type 2 and non–type 2 pathways. This multicenter phase IIA study evaluated the safety and efficacy of GSK3772847, a human mAb directed against the IL-33 receptor (IL-33R) in subjec...